Literature DB >> 29732742

Gene variants in the folate pathway are associated with increased levels of folate receptor autoantibodies.

Yuqi Dong1, Linlin Wang1, Yunping Lei2, Na Yang1, Robert M Cabrera2, Richard H Finnell2, Aiguo Ren1.   

Abstract

BACKGROUND: Folate receptors (FRs) facilitate embryonic uptake of folates and are important for proper early embryonic development. There is accumulating evidence that blocking FR autoantibodies contribute to developmental diseases. However, genetic factors associated with the expression of FR autoantibodies remain unknown.
OBJECTIVE: We investigated the effects of genetic polymorphisms in folate pathway genes on FR autoantibody titers in women.
METHODS: We recruited 302 pregnant women in China. The FR antigen-down immunoassay was used to measure levels of FR autoantibodies including human immunoglobulin G (IgG) and immunoglobulin M (IgM) in maternal plasma. Genotypes were identified by matrix-assisted laser desorption/ionization time of flight mass spectrometry and polymerase chain reaction methods. General linear model was used to analyze the effects of genetic variants on FR autoantibody levels.
RESULTS: Significant associations were observed between genotypic variations and levels of FR autoantibodies. Plasma levels of FR autoantibodies in women with the TT genotype at MTHFR rs1801133 were significantly higher than those of women with the CC genotype (IgG: β = 0.62, 95% CI 0.21-1.04; IgM: β = 0.42, 95% CI 0.12-0.72). For DNMT3A rs7560488, the level of FR autoantibody IgG significantly increased in the TT genotype compared with CC genotype (β = 0.90, 95% CI 0.20-1.59). For MTHFD2 rs828903, genotype GG was associated with elevated levels of FR autoantibody IgM compared to the AA genotype (β = 0.60, 95% CI 0.10-1.10). No association was detected between genetic variants of the DHFR gene with FR autoantibodies levels.
CONCLUSION: Genetic variations in MTHFR, DNMT3A, and MTHFD2 genes were associated with elevated plasma levels of FR autoantibodies.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  IgG; IgM; autoantibody; folate receptor; genetic polymorphisms

Mesh:

Substances:

Year:  2018        PMID: 29732742      PMCID: PMC6276117          DOI: 10.1002/bdr2.1334

Source DB:  PubMed          Journal:  Birth Defects Res            Impact factor:   2.344


  32 in total

Review 1.  Understanding the immunobiology of pregnancy and applying it to treatment of recurrent pregnancy loss.

Authors:  C B Coulam
Journal:  Early Pregnancy       Date:  2000-01

2.  Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development.

Authors:  J A Piedrahita; B Oetama; G D Bennett; J van Waes; B A Kamen; J Richardson; S W Lacey; R G Anderson; R H Finnell
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

3.  Association between Hcy levels and the CBS844ins68 and MTHFR C677T polymorphisms with essential hypertension.

Authors:  Weijuan Cai; Liang Yin; Fang Yang; Lei Zhang; Jiang Cheng
Journal:  Biomed Rep       Date:  2014-09-05

Review 4.  Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease.

Authors:  Hieronim Jakubowski
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

5.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

Authors:  N M van der Put; F Gabreëls; E M Stevens; J A Smeitink; F J Trijbels; T K Eskes; L P van den Heuvel; H J Blom
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

6.  The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population.

Authors:  Anne Parle-McDermott; Faith Pangilinan; James L Mills; Peadar N Kirke; Eileen R Gibney; James Troendle; Valerie B O'Leary; Anne M Molloy; Mary Conley; John M Scott; Lawrence C Brody
Journal:  Am J Med Genet A       Date:  2007-06-01       Impact factor: 2.802

7.  New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy?

Authors:  William G Johnson; Edward S Stenroos; John R Spychala; Sansnee Chatkupt; Sue X Ming; Steven Buyske
Journal:  Am J Med Genet A       Date:  2004-02-01       Impact factor: 2.802

8.  Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis.

Authors:  Anetta Undas; Joanna Perła; Mariusz Lacinski; Wiesław Trzeciak; Radosław Kaźmierski; Hieronim Jakubowski
Journal:  Stroke       Date:  2004-05-06       Impact factor: 7.914

9.  Antibodies to folate receptors impair embryogenesis and fetal development in the rat.

Authors:  Maria da Costa; Jeffrey M Sequeira; Sheldon P Rothenberg; Jeremy Weedon
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2003-10

Review 10.  Effects and safety of periconceptional oral folate supplementation for preventing birth defects.

Authors:  Luz Maria De-Regil; Juan Pablo Peña-Rosas; Ana C Fernández-Gaxiola; Pura Rayco-Solon
Journal:  Cochrane Database Syst Rev       Date:  2015-12-14
View more
  3 in total

1.  The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid.

Authors:  Robert M Cabrera; Jaclyn P Souder; John W Steele; Lythou Yeo; Gabriel Tukeman; Daniel A Gorelick; Richard H Finnell
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

2.  CIC de novo loss of function variants contribute to cerebral folate deficiency by downregulating FOLR1 expression.

Authors:  Xuanye Cao; Annika Wolf; Sung-Eun Kim; Robert M Cabrera; Bogdan J Wlodarczyk; Huiping Zhu; Margaret Parker; Ying Lin; John W Steele; Xiao Han; Vincent Th Ramaekers; Robert Steinfeld; Richard H Finnell; Yunping Lei
Journal:  J Med Genet       Date:  2020-08-20       Impact factor: 6.318

Review 3.  Maternal folic acid and multivitamin supplementation: International clinical evidence with considerations for the prevention of folate-sensitive birth defects.

Authors:  R D Wilson; D L O'Connor
Journal:  Prev Med Rep       Date:  2021-10-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.